Company intelligence / Profile preview

ProtoKinetix

Dalton, Ohio, United Statesprotokinetix.com ↗

Ownership: Public · PKTX
Employees: ~5
Development stage: Phase 1

Overview

ProtoKinetix has developed a patented molecule called AAGP®, an anti-aging glycopeptide with demonstrated abilities to protect cells from inflammation and extreme conditions. The company’s research suggests potential transformative applications in ophthalmology, dermatology, organ transplantation, and biomanufacturing. Clinical results are primarily pre-clinical or early-stage; there are no reported late-phase clinical trial outcomes as of May 2025.[1][3][4]

Therapeutic areas: ImmunologyOtherDermatologyOphthalmology
Modalities: Glycopeptides (specifically anti-aging glycopeptides/AAGP®)anti-freeze glycoproteins (AFGPs)
Industry: Biotech

Drug pipeline

1 asset

PKX-001

Financials

Market cap: $78.3K
Total revenue: $0
Enterprise value: $77.2K

Beyond the preview

Go deeper on ProtoKinetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProtoKinetix.

Explore the full profile